• 5179 Citations
  • 36 h-Index
1977 …2022
If you made any changes in Pure, your changes will be visible here soon.

Research Output 1978 2019

Filter
Review article
2018

Schweinfurthins: Lipid Modulators with Promising Anticancer Activity

Koubek, E. J., Weissenrieder, J. S., Neighbors, J. & Hohl, R., Aug 1 2018, In : Lipids. 53, 8, p. 767-784 18 p.

Research output: Contribution to journalReview article

Modulators
Lipids
Neoplasms
Cells
trans-Golgi Network
2012
24 Citations (Scopus)

Is there a future for prenyltransferase inhibitors in cancer therapy?

Holstein, S. A. & Hohl, R., Jan 1 2012, In : Current Opinion in Pharmacology. 12, 6, p. 704-709 6 p.

Research output: Contribution to journalReview article

Dimethylallyltranstransferase
Clinical Trials
Farnesyltranstransferase
Prenylation
Post Translational Protein Processing
9 Citations (Scopus)

Therapeutic additions and possible deletions in oncology in 2011

Holstein, S. A. & Hohl, R., Jan 1 2012, In : Clinical pharmacology and therapeutics. 91, 1, p. 15-17 3 p.

Research output: Contribution to journalReview article

United States Food and Drug Administration
Therapeutic Uses
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Non-Hodgkin's Lymphoma
2011
11 Citations (Scopus)

Clinical pharmacology as a foundation for translational science

Waldman, S. A., Hohl, R., Kearns, G. L., Swan, S. J. & Terzic, A., Jul 1 2011, In : Clinical pharmacology and therapeutics. 90, 1, p. 10-13 4 p.

Research output: Contribution to journalReview article

Translational Medical Research
Clinical Pharmacology
National Institutes of Health (U.S.)
Molecular Biology
Delivery of Health Care
2009
52 Citations (Scopus)

The intermediate enzymes of isoprenoid metabolism as anticancer targets

Wiemer, A. J., Hohl, R. & Wiemer, D. F., Jan 1 2009, In : Anti-Cancer Agents in Medicinal Chemistry. 9, 5, p. 526-542 17 p.

Research output: Contribution to journalReview article

Terpenes
Enzymes
mevalonate kinase
Neoplasms
Proteins
2006
99 Citations (Scopus)

Anti-cancer therapy: Targeting the mevalonate pathway

Swanson, K. M. & Hohl, R., Feb 1 2006, In : Current Cancer Drug Targets. 6, 1, p. 15-37 23 p.

Research output: Contribution to journalReview article

Mevalonic Acid
Transferases
Post Translational Protein Processing
Neoplasms
Clinical Trials
2004
116 Citations (Scopus)

Isoprenoids: Remarkable diversity of form and function

Holstein, S. A. & Hohl, R., Apr 1 2004, In : Lipids. 39, 4, p. 293-309 17 p.

Research output: Contribution to journalReview article

Terpenes
Hydroxymethylglutaryl CoA Reductases
ras Proteins
Critical Pathways
Diterpenes
2003
13 Citations (Scopus)

Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft

Lee, C. K., de Magalhaes-Silverman, M., Hohl, R., Hayashi, M., Buatti, J., Wen, B. C., Schlueter, A., Strauss, R. G. & Gingrich, R. D., Jan 1 2003, In : Bone Marrow Transplantation. 31, 2, p. 121-128 8 p.

Research output: Contribution to journalReview article

Homologous Transplantation
Graft vs Host Disease
Bone Marrow Transplantation
Tissue Donors
T-Lymphocytes
1989
20 Citations (Scopus)

Nonmalignant complications of therapy for Hodgkin's disease

Hohl, R. & Schilsky, R. L., Jan 1 1989, In : Hematology/Oncology Clinics of North America. 3, 2, p. 331-343 13 p.

Research output: Contribution to journalReview article

Hodgkin Disease
Survivors
Therapeutics
Poisons
Virus Diseases